Rituxan (rituximab)

P3, N=30, Recruiting, Assiut University | Trial completion date: Nov 2022 --> Nov 2026 | Trial primary completion date: Nov 2022 --> Nov 2026

P=N/A, N=200, Not yet recruiting, Tongji Hospital

Although IR2 showed initial activity in TP53-mutated patients, it did not completely overcome their poor prognosis. However, the IR2 regimen may serve as a bridge to allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy.

P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2025 --> Nov 2026

After five cycles of R-MPV (rituximab, methotrexate, procarbazine, vincristine) therapy and three cycles of R-ESHAP (rituximab, etoposide, cytarabine, cisplatin, methylprednisolone) therapy, the patient received autologous hematopoietic stem cell transplantation using R-MEAM (rituximab, ranimustine, etoposide, cytarabine, melphalan) regimen after bridging therapy with ibrutinib. He did not relapse within 3 years of transplantation. To the best of our knowledge, this is the first case report of DLBCL and MCL coexistence.

DEL status is strongly linked to poor survival in DLBCL, highlighting the need for targeted therapies beyond R-CHOP. Future research should explore personalized treatment strategies to improve outcomes in this high-risk group.

Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, pirtobrutinib, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection. Most patients succumb to causes unrelated to macroglobulinemia.

P1, N=62, Completed, Celgene | Active, not recruiting --> Completed | Phase classification: P1/2 --> P1

P3, N=75, Active, not recruiting, Hopital Foch | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Jul 2025

Rituximab has revolutionized FL treatment, significantly improving overall survival over the past two decades...While FL remains incurable, advances in immunochemotherapy and targeted therapies have improved outcomes. This review provides a comprehensive overview of prognostic tools in FL, emphasizing the importance of risk stratification for personalized treatment strategies.

P3, N=529, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jan 2026

P3, N=547, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026

The patient received three lines of anti-neoplastic therapy (R-CHOP, R-CHOEP and SYHX1903) and achieved stable disease for 6 years. Due to the patient suffering from heart failure after the third line of the previous chemotherapy, palliative radiotherapy was administered to the left forearm, and the patient achieved a partial response. In conclusion, primary gingival DLBCL with muscle invasion is rare and easily misdiagnosed, and individualized treatment should be considered for these complex cases.

P1, N=18, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting

P1/2, N=22, Enrolling by invitation, St. Petersburg State Pavlov Medical University

The mean age of the disease was found to be a decade earlier than other parts of the world, with a higher preponderance of women. The most common comorbidities were hypertension and diabetes mellitus. Most deaths were due to infectious and cardiovascular diseases. Mortality rate was 1/3 in patients who received RTX compared to those who were treated with high dose corticosteroids and other immunosuppressive agents.

This study examines the frequency of recurring gene mutations and their interplay with well-known biomarkers in female and male patients between 18 and 80 years with ref/rel DLBCL compared to patients with complete remission (CR) to identify biological risk factors associated with treatment response, using cohorts of R-CHOP-like treated DLBCL enrolled in clinical trials of the DSHNHL...Mutations in CREBBP and TNFRSF14 were associated with shorter overall survival (OS) only in younger patients. A higher proportion of GNA13 mutations was detected in female patients of the elderly DLBCL patient cohort, clearly emphasizing the striking differences in biomarker distribution between younger and elderly as well as female and male patients.

P1/2, N=304, Recruiting, Genmab | N=184 --> 304

P1, N=20, Recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Dec 2025 --> Dec 2026

P1/2, N=28, Recruiting, City of Hope Medical Center | Phase classification: P1 --> P1/2

P1/2, N=37, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Dec 2025

All four biosimilar BsAbs demonstrated superior in vitro activity to rituximab, with biosimilar glofitamab consistently being the most potent. Moreover, biosimilar glofitamab and odronextamab retained significant activity in the presence of low-level CD20 expression. Finally, one DLBCL cell line exhibited intrinsic resistance to all four CD20xCD3 BsAbs despite inducing marked T-cell and NK-cell activation.

The GAINED study (NCT01659099) was a randomized phase 3 trial comparing obinutuzumab (G) to rituximab (R) plus ACVBP or CHOP14 induction, followed by PET-guided consolidation. In a multivariate model including Bulk, aaIPI, and ΔSUVmax PET2/PET4, only Bulk and ΔSUVmax PET4 ≤70% were associated with shorter PFS (HR 4.39 [1.28-15.11] and 4.95 [1.71-14.3], respectively), while none were associated with OS. The ΔSUVmax-based interim PET4 response emerged as the strongest predictor of patient outcomes in this selected clinical trial population.

The patient was initially stabilized with a prephase regimen of cyclophosphamide, vincristine, and prednisone (COP), followed by induction and consolidation with R-COPADM (rituximab, cyclophosphamide, vincristine, prednisone, and methotrexate). At follow-up, the patient remains in clinical remission with no signs of progression. This case highlights the importance of early recognition, detailed histopathological evaluation, and the role of immunohistochemistry in accurately diagnosing THRLBCL in children, ensuring timely initiation of effective therapy and improving outcomes in this rare pediatric malignancy.

We comprehensively defined BCL-2 dependence as a potential functional and predictive biomarker of treatment response in CLL, underscoring the importance of characterizing apoptotic signaling in CLL to stratify patients beyond genetic markers and identifying novel combinations to exploit BCL-2 dependence therapeutically. Our approach has the potential to help optimize targeted therapy combinations for CLL patients.

P=N/A, N=100, Not yet recruiting, Novartis Pharmaceuticals

This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).

P3, N=250, Not yet recruiting, BeiGene

P1, N=48, Active, not recruiting, Kami Maddocks, MD | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Mar 2014 --> May 2025

P2, N=50, Not yet recruiting, Sun Yat-sen University

P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Mar 2029 --> Sep 2028 | Trial primary completion date: Mar 2029 --> Sep 2028

Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial (NCT02005471) resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab (BR). No new safety findings were observed. Overall, these final MURANO analyses support consideration of fixed-duration VenR therapy for patients with relapsed/refractory CLL.

In conclusion, the integrated approach reveals that lncRNAs HOTAIR and MALAT1 were upregulated, while lncRNA PANDA was downregulated in DLBCL patients compared with controls, and the three lncRNAs closely associated with clinical prognosis. This study warrants future studies in clinical trials for the treatment of R-CHOP-resistant DLBCL patients.

This study identified a prognostically relevant LYZ+ fibroblasts and FN1+ macrophages in DLBCL. The hub genes associated with these subtypes represent potential biomarkers, providing insights into improving patient outcomes in DLBCL.

Chemoimmunotherapy with fludarabine/cladribine, cyclophosphamide and rituximab have been almost completely replaced by targeted therapies with small molecules such as Bruton's tyrosine kinase inhibitors or B-cell lymphoma 2 (BCL-2) antagonists. The variable clinical course of disease requires personalization and individualized treatment to achieve the optimal survival outcome and acceptable safety profile, especially in the case of poor prognosis. Clinical trials performed in the past decade indicate that novel drugs, used as a single agent or as part of a conventional chemotherapy, offer promise in minimalizing relapse rates, and may allow more effective and safer treatment options by reducing the risk of adverse events, especially cytopenias and infections.

P4, N=60, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

PTEN presence, BCL2 mutations, and low or undetectable baseline IL-2 levels were associated with improved patient survival following treatment with C + R, supporting a potential role for these biomarkers in guiding treatment selection for patients with indolent non-Hodgkin lymphoma.

A 58-year-old woman in Belgium with a history of follicular lymphoma treated with rituximab sought care for a rapid sensory-motor deficit. High CXC motif chemokine ligand 13 levels and PCR confirmed the diagnosis. Ceftriaxone treatment led to full recovery.

P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center

The scleritis was successfully treated with a tapering dose of corticosteroids and rituximab. This case illustrates a rare presentation of scleritis as an IgG4-RD (in a more precise way AAV and IgG4-RD overlap syndrome) and demonstrates that rituximab and low dose of corticosteroids can lead to remission.

Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.).

P1, N=29, Completed, AbbVie | Active, not recruiting --> Completed